Overview

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
0
Participant gender:
All
Summary
Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in high-risk MDS patients undergoing allo-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First People's Hospital of Chenzhou
Guangzhou First People's Hospital
Institute of Hematology and Blood Diseases Hospital
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Seventh Affiliated Hospital of Sun Yat-sen University
Treatments:
Busulfan
Cyclophosphamide
Decitabine
Fludarabine
Lenograstim
Criteria
Inclusion Criteria:

- Had a diagnosis of RAEB-1 or RAEB-2 with IPSS-R >3

- Age 18 to 65 years old

- ECOG performance status of 0-2

- HCT-CI of 0-2

- Were willing to undergo allo-HSCT

Exclusion Criteria:

- Therapy-related MDS

- Previous allo-HSCT

- Uncontrolled infections

- Liver or renal dysfunction

- Severe concomitant conditions not suitable for the trial